Trial Profile
A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms HCC-DPPIV
- 17 Oct 2018 Status changed from recruiting to completed.
- 27 Sep 2017 Planned End Date changed from 1 Jul 2018 to 1 Feb 2019.
- 27 Sep 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2018.